• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Prophylactic Central Neck Dissection in Papillary Thyroid Carcinoma: All Risks, No Reward.预防性中央区颈部清扫术在甲状腺乳头状癌中的应用:全是风险,没有获益。
J Surg Res. 2021 Aug;264:230-235. doi: 10.1016/j.jss.2021.02.035. Epub 2021 Apr 8.
2
Rationality in prophylactic central neck dissection in clinically node-negative (cN0) papillary thyroid carcinoma: Is there anything more to say? A decade experience in a single-center.临床颈淋巴结阴性(cN0)甲状腺乳头状癌预防性中央区颈淋巴结清扫的合理性:还有什么可说的吗?单中心十年经验。
Int J Surg. 2017 May;41 Suppl 1:S40-S47. doi: 10.1016/j.ijsu.2017.01.113.
3
Long-term outcomes of central neck dissection for cN0 papillary thyroid carcinoma.cN0 期乳头状甲状腺癌中央区颈淋巴结清扫的长期预后
Am J Otolaryngol. 2017 Sep-Oct;38(5):576-581. doi: 10.1016/j.amjoto.2017.06.004. Epub 2017 Jun 14.
4
Level VII is an important component of central neck dissection for papillary thyroid cancer.VII 级是甲状腺乳头状癌中央区颈部淋巴结清扫术的重要组成部分。
Ann Surg Oncol. 2013 Jul;20(7):2261-5. doi: 10.1245/s10434-012-2833-1. Epub 2013 Jan 30.
5
Central neck dissection for papillary thyroid cancer.甲状腺乳头状癌的中央区颈部清扫术
Arch Otolaryngol Head Neck Surg. 2009 Nov;135(11):1092-7. doi: 10.1001/archoto.2009.158.
6
Comparison of prophylactic ipsilateral and bilateral central lymph node dissection in papillary thyroid carcinoma: a meta-analysis.比较甲状腺乳头状癌预防性同侧和双侧中央区淋巴结清扫术的效果:一项荟萃分析。
Braz J Otorhinolaryngol. 2023 Nov-Dec;89(6):101318. doi: 10.1016/j.bjorl.2023.101318. Epub 2023 Sep 4.
7
Complications of central neck dissection in patients with papillary thyroid carcinoma: results of a study on 1087 patients and review of the literature.中央区颈部清扫术在甲状腺乳头状癌患者中的并发症:对 1087 例患者的研究结果及文献复习。
Thyroid. 2012 Sep;22(9):911-7. doi: 10.1089/thy.2012.0011. Epub 2012 Jul 24.
8
The extent of lymph node yield in central neck dissection can be affected by preoperative and intraoperative assessment and alter the prognosis of papillary thyroid carcinoma.中央区颈淋巴结清扫术中淋巴结的获取程度会受到术前和术中评估的影响,并改变甲状腺乳头状癌的预后。
Cancer Med. 2020 Feb;9(3):1017-1024. doi: 10.1002/cam4.2762. Epub 2019 Dec 18.
9
Local lymph node recurrence after central neck dissection in papillary thyroid cancers: A meta analysis.甲状腺乳头状癌中央区淋巴结清扫术后局部淋巴结复发:荟萃分析。
Eur Ann Otorhinolaryngol Head Neck Dis. 2019 Nov;136(6):481-487. doi: 10.1016/j.anorl.2018.07.010. Epub 2019 Jun 10.
10
A prospective randomized controlled trial to assess the efficacy and safety of prophylactic central compartment lymph node dissection in papillary thyroid carcinoma.一项前瞻性随机对照试验,旨在评估预防性中央区淋巴结清扫术在甲状腺乳头状癌中的疗效和安全性。
Surgery. 2022 Jan;171(1):182-189. doi: 10.1016/j.surg.2021.03.071. Epub 2021 Aug 12.

引用本文的文献

1
Safety enhancement of improved hydrodissection for microwave ablation in lymph node metastasis from papillary thyroid carcinoma: a comparative study.改良水分离技术用于甲状腺乳头状癌淋巴结转移微波消融的安全性增强:一项对比研究
Front Endocrinol (Lausanne). 2025 Jul 23;16:1594561. doi: 10.3389/fendo.2025.1594561. eCollection 2025.
2
Correlation between preoperative uric acid levels and lymph node metastases in patients with papillary thyroid cancer: a retrospective study.甲状腺乳头状癌患者术前尿酸水平与淋巴结转移的相关性:一项回顾性研究
PeerJ. 2025 Jul 10;13:e19410. doi: 10.7717/peerj.19410. eCollection 2025.
3
Ambulatory endoscopic thyroidectomy via a unilateral-axillary approach has an acceptable safety profile for thyroid nodule.经单侧腋窝入路的门诊内镜甲状腺切除术对甲状腺结节具有可接受的安全性。
Updates Surg. 2025 Jun 21. doi: 10.1007/s13304-025-02287-x.
4
Central Neck Dissection in Papillary Thyroid Carcinoma: Benefits and Doubts in the Era of Thyroid Lobectomy.甲状腺乳头状癌的中央区颈淋巴结清扫术:甲状腺叶切除术时代的益处与疑问
Biomedicines. 2024 Sep 25;12(10):2177. doi: 10.3390/biomedicines12102177.
5
Prediction Model of Cervical Lymph Node Metastasis in Papillary Thyroid Carcinoma.甲状腺乳头状癌颈淋巴结转移预测模型。
Cancer Control. 2024 Jan-Dec;31:10732748241295347. doi: 10.1177/10732748241295347.
6
Risk stratification for central lymph node metastasis in mono-focal papillary thyroid carcinoma patients with encapsulated tumor as confirmed by preoperative ultrasound: a multi-center analysis.术前超声证实包膜内单发甲状腺乳头状癌患者中央区淋巴结转移风险分层:多中心分析。
Endocrine. 2024 Dec;86(3):1045-1054. doi: 10.1007/s12020-024-03861-w. Epub 2024 Jul 25.
7
Development and validation of a clinical predictive model for high-volume lymph node metastasis of papillary thyroid carcinoma.开发和验证甲状腺乳头状癌高容量淋巴结转移的临床预测模型。
Sci Rep. 2024 Jul 9;14(1):15828. doi: 10.1038/s41598-024-66304-6.
8
Nomogram to predict central lymph node metastasis in papillary thyroid carcinoma.列线图预测甲状腺乳头状癌中央区淋巴结转移。
Clin Exp Metastasis. 2024 Oct;41(5):613-626. doi: 10.1007/s10585-024-10285-3. Epub 2024 Apr 3.
9
Ultrasound radiomics models based on multimodal imaging feature fusion of papillary thyroid carcinoma for predicting central lymph node metastasis.基于甲状腺乳头状癌多模态成像特征融合的超声放射组学模型预测中央淋巴结转移
Front Oncol. 2023 Oct 30;13:1261080. doi: 10.3389/fonc.2023.1261080. eCollection 2023.
10
Predictive factors of lymph node metastasis in papillary thyroid cancer.甲状腺乳头状癌淋巴结转移的预测因素。
PLoS One. 2023 Nov 27;18(11):e0294594. doi: 10.1371/journal.pone.0294594. eCollection 2023.

本文引用的文献

1
Practice patterns for surgical management of low-risk papillary thyroid cancer from 2014 to 2019: A CESQIP analysis.2014 年至 2019 年低危型甲状腺乳头状癌手术治疗方式的实践模式:CESQIP 分析。
Am J Surg. 2021 Feb;221(2):448-454. doi: 10.1016/j.amjsurg.2020.07.032. Epub 2020 Aug 21.
2
Prophylactic central lymph node dissection informs the decision of radioactive iodine ablation in papillary thyroid cancer.预防性中央淋巴结清扫术为甲状腺乳头状癌放射性碘消融治疗提供决策依据。
Am J Surg. 2021 May;221(5):886-892. doi: 10.1016/j.amjsurg.2020.08.012. Epub 2020 Aug 18.
3
Prophylactic Central Neck Dissection for Papillary Thyroid Carcinoma with Clinically Uninvolved Central Neck Lymph Nodes: A Systematic Review and Meta-analysis.中央区颈部淋巴结临床未受累的甲状腺乳头状癌预防性中央区颈部淋巴结清扫术:一项系统评价和Meta分析
World J Surg. 2018 Sep;42(9):2846-2857. doi: 10.1007/s00268-018-4547-4.
4
Thyroid Cancer: Risk-Stratified Management and Individualized Therapy.甲状腺癌:风险分层管理与个体化治疗。
Clin Cancer Res. 2016 Oct 15;22(20):5012-5021. doi: 10.1158/1078-0432.CCR-16-0484.
5
Prophylactic Central Neck Dissection Might Not Be Necessary in Papillary Thyroid Carcinoma: Analysis of 11,569 Cases from a Single Institution.预防性中央区淋巴结清扫术在甲状腺乳头状癌中并非必需:单中心 11569 例病例分析。
J Am Coll Surg. 2016 May;222(5):853-64. doi: 10.1016/j.jamcollsurg.2016.02.001. Epub 2016 Feb 13.
6
Nodal metastases in thyroid cancer: prognostic implications and management.甲状腺癌的淋巴结转移:预后意义及处理
Future Oncol. 2016 Apr;12(7):981-94. doi: 10.2217/fon.16.10. Epub 2016 Mar 7.
7
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.2015年美国甲状腺协会成人甲状腺结节和分化型甲状腺癌管理指南:美国甲状腺协会甲状腺结节和分化型甲状腺癌指南工作组
Thyroid. 2016 Jan;26(1):1-133. doi: 10.1089/thy.2015.0020.
8
The Impact of Subclinical Disease and Mechanism of Detection on the Rise in Thyroid Cancer Incidence: A Population-Based Study in Olmsted County, Minnesota During 1935 Through 2012.亚临床疾病及检测机制对甲状腺癌发病率上升的影响:1935年至2012年明尼苏达州奥尔姆斯特德县的一项基于人群的研究
Thyroid. 2015 Sep;25(9):999-1007. doi: 10.1089/thy.2014.0594. Epub 2015 Jul 30.
9
Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: clinical implications derived from the first prospective randomized controlled single institution study.甲状腺乳头状癌预防性中央区淋巴结清扫术:来自首个前瞻性随机对照单机构研究的临床意义
J Clin Endocrinol Metab. 2015 Apr;100(4):1316-24. doi: 10.1210/jc.2014-3825. Epub 2015 Jan 15.
10
Controversies in primary treatment of low-risk papillary thyroid cancer.低危型甲状腺乳头状癌的初级治疗争议。
Lancet. 2013 Mar 23;381(9871):1046-57. doi: 10.1016/S0140-6736(12)62205-3. Epub 2013 Mar 22.

预防性中央区颈部清扫术在甲状腺乳头状癌中的应用:全是风险,没有获益。

Prophylactic Central Neck Dissection in Papillary Thyroid Carcinoma: All Risks, No Reward.

机构信息

Department of Surgery, The University of Alabama at Birmingham, Birmingham, Alabama.

Department of Otolaryngology, The University of Alabama at Birmingham, Birmingham, Alabama.

出版信息

J Surg Res. 2021 Aug;264:230-235. doi: 10.1016/j.jss.2021.02.035. Epub 2021 Apr 8.

DOI:10.1016/j.jss.2021.02.035
PMID:33838407
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8222095/
Abstract

BACKGROUND

Central neck dissection (CND) remains a controversial intervention for papillary thyroid carcinoma (PTC) patients with clinically negative nodes (cN0) in the central compartment. Proponents state that CND in cN0 patients prevents locoregional recurrence, while opponents deem that the risks of complications outweigh any potential benefit. Thus, there remains conflicting results amongst studies assessing oncologic and surgical outcomes in cN0 PTC patients who undergo CND. To provide clarity to this controversy, we sought to evaluate the efficacy, safety, and oncologic impact of CND in cN0 PTC patients at our institution.

MATERIALS AND METHODS

Six hundred and ninety-five patients with PTC who underwent thyroidectomy at our institution between 1998 and 2018 were identified using an institutional cancer registry and supplemental electronic medical record queries. Patients were stratified by whether or not they underwent CND; identified as CND(+) or CND(-), respectively. Patients were also stratified by whether or not they received adjuvant radioactive iodine (RAI) therapy. Patient demographics, pathologic results, as well as surgical and oncologic outcomes were reviewed. Standard statistical analyses were performed using ANOVA and/or t-test and chi-squared tests as appropriate.

RESULTS

Among the 695 patients with PTC, 492 (70.8%) had clinically and radiographically node negative disease (cN0). The mean age was 50 ± 1 years old and 368 (74.8%) were female. Of those with cN0 PTC, 61 patients (12.4%) underwent CND. CND(+) patients were found to have higher preoperative thyroid stimulating hormone (TSH) values, 2.8 ± 0.8 versus 1.5 ± 0.2 mU/L (P = 0.028) compared to CND(-) patients. CND did not significantly decrease disease recurrence, development of distant metastatic disease (P = 0.105) or persistence of disease (P = 0.069) at time of mean follow-up of 38 ± 3 months compared to CND(-) patients. However, surgical morbidity rates were significantly higher in CND(+) patients; including transient hypocalcemia (36.1% versus 14.4%; P < 0.001), transient recurrent laryngeal nerve (RLN) injury (19.7% vers us 7.0%; P < 0.001), and permanent RLN injury (3.3% versus 0.7%; P < 0.001).

CONCLUSIONS

The majority of patients at our institution with cN0 PTC did not undergo CND. This data suggests that CND was not associated with improvements in oncologic outcomes during the short-term follow-up period and led to increased postoperative morbidity. Therefore, we conclude that CND should not be routinely performed for patients with cN0 PTC.

摘要

背景

中央颈部清扫术(CND)对于临床淋巴结阴性(cN0)的甲状腺乳头状癌(PTC)患者仍然是一种有争议的干预措施。支持者认为,CND 可预防局部区域复发,而反对者则认为并发症的风险超过任何潜在的益处。因此,在评估接受 CND 的 cN0 PTC 患者的肿瘤学和手术结果的研究中,仍然存在相互矛盾的结果。为了解决这一争议,我们试图评估我们机构中 cN0 PTC 患者 CND 的疗效、安全性和肿瘤学影响。

材料和方法

使用机构癌症登记处和补充电子病历查询,在我们机构 1998 年至 2018 年间接受甲状腺切除术的 695 名 PTC 患者。患者根据是否接受 CND 进行分层;分别为 CND(+)或 CND(-)。患者还根据是否接受辅助放射性碘(RAI)治疗进行分层。回顾患者的人口统计学数据、病理结果以及手术和肿瘤学结果。使用 ANOVA 和/或 t 检验和卡方检验进行适当的标准统计分析。

结果

在 695 名 PTC 患者中,492 名(70.8%)临床和影像学淋巴结阴性(cN0)。平均年龄为 50±1 岁,368 名(74.8%)为女性。在 cN0 PTC 患者中,61 名(12.4%)接受了 CND。与 CND(-)患者相比,CND(+)患者的术前甲状腺刺激激素(TSH)值更高,分别为 2.8±0.8 与 1.5±0.2 mU/L(P=0.028)。与 CND(-)患者相比,CND 并未显著降低疾病复发、远处转移疾病(P=0.105)或疾病持续存在(P=0.069)的风险。然而,在平均 38±3 个月的随访期间,CND(+)患者的手术发病率明显更高;包括短暂性低钙血症(36.1%比 14.4%;P<0.001)、短暂性喉返神经(RLN)损伤(19.7%比 7.0%;P<0.001)和永久性 RLN 损伤(3.3%比 0.7%;P<0.001)。

结论

我们机构的大多数 cN0 PTC 患者未接受 CND。该数据表明,在短期随访期间,CND 并未改善肿瘤学结果,并导致术后发病率增加。因此,我们得出结论,CND 不应常规用于 cN0 PTC 患者。